Posted by Michael Wonder on 01 Nov 2019
ICER report finds oral GLP-1 semaglutide, at estimated net price, less cost-effective than SGLT-2 competitor empagliflozin as add-on therapy for type 2 diabetes
1 November 2019 - Semaglutide as add-on therapy to metformin achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than empagliflozin.
The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of oral semaglutide (Rybelsus, Novo Nordisk), a GLP-1 receptor agonist for the treatment of Type 2 diabetes mellitus.
This new therapy is an oral version of the injectable Ozempic (Novo Nordisk), which was approved by the FDA in 2017. For this analysis, oral semaglutide was compared to background therapy with metformin alone, and to three competitors for add-on therapy: liraglutide (Victoza, Novo Nordisk), sitagliptin (Januvia, Merck), and empagliflozin (Jardiance, Boehringer Ingelheim).
